MedTrace Logo

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2013-07-15

No results posted yet for this study

Summary

Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival. In the setting of increasingly effective systemic therapy and limited metastatic disease, aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival.

Conditions

  • Stage IV or Recurrent Carcinoma or Sarcoma

Interventions

PROCEDURE

Complete Surgical Removal

RADIATION

Stereotactic Radiosurgery

RADIATION

Ablative external beam radiation dose

PROCEDURE

Subtotal surgical removal plus ablative radiation dose

Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment

RADIATION

Radioembolization

radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques

Sponsors & Collaborators

  • Rocky Mountain Cancer Centers

    lead OTHER

Principal Investigators

  • Dennise Carter, MD · Rocky Mountain Cancer Centers

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01898962 on ClinicalTrials.gov